CR20130338A - Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos - Google Patents

Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos

Info

Publication number
CR20130338A
CR20130338A CR20130338A CR20130338A CR20130338A CR 20130338 A CR20130338 A CR 20130338A CR 20130338 A CR20130338 A CR 20130338A CR 20130338 A CR20130338 A CR 20130338A CR 20130338 A CR20130338 A CR 20130338A
Authority
CR
Costa Rica
Prior art keywords
same
heterocyclic compounds
substituted nitrogen
nitrogen heterocyclic
compounds fused
Prior art date
Application number
CR20130338A
Other languages
English (en)
Inventor
Lewis J Gazzard
Emily Hanan
Samuel Kintz
Joseph P Lyssikatos
Hans Edward Purkey
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20130338A publication Critical patent/CR20130338A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La invención proporciona nuevos compuestos que tienen la fórmula general: (I) en la que X1 es N o N+O-, y uno de X2, X3 y X4 es N o N+-O- y los demás de X2, X3 y X4 son C. R2, R3, R4, R5, R6, A, B y Y tienen los significados aquí definidos. Se describen además composiciones de compuestos de la fórmula I y métodos de uso.
CR20130338A 2010-12-17 2013-07-10 Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos CR20130338A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424567P 2010-12-17 2010-12-17
PCT/EP2011/072666 WO2012080284A2 (en) 2010-12-17 2011-12-14 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof

Publications (1)

Publication Number Publication Date
CR20130338A true CR20130338A (es) 2013-08-09

Family

ID=45418653

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130338A CR20130338A (es) 2010-12-17 2013-07-10 Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos

Country Status (18)

Country Link
US (3) US8623889B2 (es)
EP (1) EP2651899B1 (es)
JP (2) JP6026427B2 (es)
KR (1) KR20130129244A (es)
CN (1) CN103261167B (es)
AR (1) AR084280A1 (es)
AU (1) AU2011344270A1 (es)
BR (1) BR112013013790A2 (es)
CA (1) CA2817460A1 (es)
CO (1) CO6741198A2 (es)
CR (1) CR20130338A (es)
EA (1) EA026115B1 (es)
EC (1) ECSP13012771A (es)
MA (1) MA34836B1 (es)
MX (1) MX2013006101A (es)
PH (1) PH12013501489A1 (es)
TW (1) TW201307292A (es)
WO (1) WO2012080284A2 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439014B2 (en) 2006-04-18 2008-10-21 Advanced Liquid Logic, Inc. Droplet-based surface modification and washing
US8809068B2 (en) 2006-04-18 2014-08-19 Advanced Liquid Logic, Inc. Manipulation of beads in droplets and methods for manipulating droplets
EP2588473A1 (en) * 2010-06-30 2013-05-08 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
TW201307292A (zh) * 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
BR112015005562A2 (pt) * 2012-09-14 2017-08-08 Eternity Bioscience Inc compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014087165A1 (en) * 2012-12-06 2014-06-12 University Of Bath Tankyrase inhibitors
EP3013825B1 (en) * 2013-06-24 2019-08-07 Amgen Inc. Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
ES2896400T3 (es) 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
TW202237569A (zh) 2014-12-24 2022-10-01 美商基利科學股份有限公司 喹唑啉化合物
ES2735087T3 (es) 2014-12-24 2019-12-16 Gilead Sciences Inc Compuestos de pirimidina fusionados para el tratamiento de VIH
EP3237397B1 (en) 2014-12-24 2018-11-21 Gilead Sciences, Inc. Isoquinoline compounds for the treatment of hiv
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
ES2846833T3 (es) 2016-07-18 2021-07-29 Janssen Pharmaceutica Nv Ligandos de obtención de imágenes de tau por PET
AU2017300123A1 (en) * 2016-07-20 2019-01-31 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as PERK inhibitors
SG11201908940UA (en) 2017-03-30 2019-10-30 Hoffmann La Roche Isoquinolines as inhibitors of hpk1
US11174255B2 (en) * 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
WO2018216705A1 (ja) * 2017-05-23 2018-11-29 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
ES2953025T3 (es) * 2017-10-02 2023-11-07 1St Biotherapeutics Inc Compuestos de benzotiazol y métodos que usan los mismos para tratar trastornos neurodegenerativos
WO2019079626A1 (en) 2017-10-19 2019-04-25 Samumed, Llc 6- (HETEROARYL 5-CHAIN) ISOQUINOLIN-3-YL CARBOXAMIDES, THEIR PREPARATION AND THEIR USE
US10653688B2 (en) 2017-10-27 2020-05-19 Samumed, Llc 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof
US10413537B2 (en) 2017-10-27 2019-09-17 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CN111868058B (zh) * 2018-05-25 2023-06-13 上海和誉生物医药科技有限公司 一种fgfr抑制剂、其制备方法和在药学上的应用
CN111936493B (zh) * 2018-06-19 2023-05-26 上海和誉生物医药科技有限公司 一种高选择性FGFRi抑制剂及其制备方法和应用
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
GB201901760D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
MX2021010122A (es) 2019-02-22 2021-09-23 1St Biotherapeutics Inc Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
US20220160902A1 (en) * 2019-03-07 2022-05-26 1ST Biotherapeutics, Inc. [18F]-Labeled Benzothiazole Derivative As PET Radiotracer
CN114269720B (zh) * 2019-07-25 2025-03-28 库拉德夫制药私人有限公司 乙酰辅酶a合成酶短链2(acss2)的小分子抑制剂
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
US11767321B2 (en) * 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
CA3195193A1 (en) * 2020-10-29 2022-05-05 Peter H. Fuller N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EP4263541A1 (en) * 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG New aryl-pyrido-pyrimidin-one derivatives
CN112898273B (zh) * 2021-03-30 2022-05-31 海南锦瑞制药有限公司 伏立康唑的合成方法及应用
US20250017914A1 (en) * 2021-09-10 2025-01-16 Black Diamond Therapeutics, Inc. 6-aza-quinoline derivatives and related uses
EP4408427A4 (en) * 2021-10-01 2025-10-15 Merck Sharp & Dohme Llc SYSTEM AND METHOD FOR STATIC AND DYNAMIC MRI COMPENSATION
CN114605267B (zh) * 2022-03-18 2024-02-23 北京格林凯默科技有限公司 2-溴-n,n-二甲基苯胺的制备方法
CN114573460B (zh) * 2022-03-18 2024-04-26 北京格林凯默科技有限公司 3-溴-n,n-二甲基苯胺的制备方法
AR128846A1 (es) 2022-03-23 2024-06-19 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg
EP4601644A1 (en) * 2022-10-14 2025-08-20 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024097953A1 (en) * 2022-11-04 2024-05-10 Enliven Inc. Naphthyridine compounds for inhibition of raf kinases
WO2024098001A1 (en) * 2022-11-04 2024-05-10 Enliven Inc. Naphthyridone compounds for inhibition of raf kinases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535321A (en) 1967-12-01 1970-10-20 Smithkline Corp 2-carbalkoxyaminodihydroquinazolines
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE3034001A1 (de) * 1980-09-10 1982-04-22 Hoechst Ag, 6000 Frankfurt Isochinolinderivate, verfahren zu ihrer hersellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
BR0013899A (pt) 1999-09-10 2003-07-08 Merck & Co Inc Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006124944A1 (en) 2005-05-18 2006-11-23 Wyeth 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same
EP1899322B1 (en) 2005-06-28 2009-09-02 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
AU2006279992A1 (en) 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
KR20100044251A (ko) 2007-08-15 2010-04-29 싸이토키네틱스, 인코포레이티드 특정 화학 물질, 조성물 및 방법
US8309577B2 (en) * 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US20100197688A1 (en) 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
GB0812969D0 (en) * 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
WO2010088177A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
TW201307292A (zh) * 2010-12-17 2013-02-16 Hoffmann La Roche 經取代之６，６－稠合含氮雜環化合物及其用途

Also Published As

Publication number Publication date
US9206175B2 (en) 2015-12-08
TW201307292A (zh) 2013-02-16
PH12013501489A1 (en) 2013-08-28
KR20130129244A (ko) 2013-11-27
WO2012080284A3 (en) 2012-09-07
CA2817460A1 (en) 2012-06-21
BR112013013790A2 (pt) 2016-09-13
AU2011344270A1 (en) 2013-07-18
ECSP13012771A (es) 2014-01-31
MX2013006101A (es) 2013-07-02
MA34836B1 (fr) 2014-01-02
CN103261167B (zh) 2016-05-04
HK1187606A1 (zh) 2014-04-11
US8623889B2 (en) 2014-01-07
JP6026427B2 (ja) 2016-11-16
US20160060262A1 (en) 2016-03-03
AR084280A1 (es) 2013-05-02
EA201390877A1 (ru) 2013-12-30
JP2014502601A (ja) 2014-02-03
EP2651899A2 (en) 2013-10-23
US20140088076A1 (en) 2014-03-27
JP2017031207A (ja) 2017-02-09
EA026115B1 (ru) 2017-03-31
EP2651899B1 (en) 2017-05-31
WO2012080284A2 (en) 2012-06-21
US20120322785A1 (en) 2012-12-20
CO6741198A2 (es) 2013-08-30
CN103261167A (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
ECSP13012771A (es) Compuestos heterocíclicos nitrogenados sustituidos fusionados en posición 6,6 y usos de los mismos
CR20150436A (es) Nuevos octahidro-pirrolo[3,4-c]-pirrol y -piridina-fenilo
CO7121325A2 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CL2019002609A1 (es) Compuestos heterocíclicos útiles como inhibidores dobles atx/ca.
ECSP10010722A (es) Compuestos orgánicos
CR20160171A (es) NUEVO OCTAHIDRO-CICLOBUTA[1,2-c; 3,4-c] DIPIRROL-2-ILO
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CR20140135A (es) Nuevos derivados de aril-quinolina
CR20150085A (es) Nuevas 6-aminoacido-heteroarildihidropirmidindas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
GT201200346A (es) Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
UY28764A1 (es) Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
BR112015022488A2 (pt) triazolopiridinas substituídas e métodos de uso das mesmas
MX2013004242A (es) Sulfonamidas nematocidas.
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CY1112886T1 (el) Ανοσοκατασταλτικος παραγοντας ο οποιος περιλαμβανει μια ετεροκυκλικη ενωση ως δραστικο συστατικο
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
UY31071A1 (es) Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
BR112013028368A2 (pt) novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona
ATE513818T1 (de) Chinazolinonderivate als tubulinpolymerisationshemmer